Treatment selection for stage IIIA Hodgkin's disease patients |
| |
Authors: | L R Prosnitz D Cooper E B Cox D S Kapp L R Farber |
| |
Institution: | 1. Duke University Medical Center, Durham, NC, USA;2. Departments of Therapeutic Radiology and Medicine, Yale University School of Medicine, New Haven, CT, USA |
| |
Abstract: | Two treatment policies for the therapy of patients with Stage IIIA Hodgkin's disease are compared. From 1969-1976, 49 newly diagnosed and pathologically staged IIIA patients received total nodal irradiation (TNI) alone (no liver irradiation). Although actuarial survival was 80% at 5 years and 68% at 10 years, actuarial freedom from relapse was only 38% at 5 years. Accordingly, a new treatment policy was instituted in 1976. Patients with either CS IIIA disease, multiple splenic nodules, IIIA with a large mediastinal mass or III2, received combined modality therapy (combination chemotherapy and irradiation). All others received TNI. Thirty-six patients have been treated under the new program. The actuarial survival is 90% at 5 years and the relapse-free survival is 87%, suggesting the superiority of this approach. |
| |
Keywords: | Treatment for Stage IIIA Hodgkin's disease |
本文献已被 ScienceDirect 等数据库收录! |
|